Small Trial Tests Neuro-Cells Safety in Chronic Spinal Cord Injury
A completed 10-patient trial tested a stem cell product for chronic spinal cord injury, but the supplied abstract reports no safety or recovery results.
Summary
A completed early-stage trial investigated Neuro-Cells, an experimental product containing fresh stem cells taken from each patient's own body, in 10 patients with chronic traumatic spinal cord injury. Researchers planned one injection into the fluid surrounding the spinal cord, with safety as the main focus. The study took place at one center, and both patients and researchers knew the treatment being given. It began in November 2020 and finished in March 2023. However, the supplied abstract does not report side effects, improvements in movement, or other outcomes. Completion alone does not show that the treatment is safe or effective. The research is relevant to efforts to restore physical function, but it offers no established treatment recommendation. This summary is based on the abstract and supplied registry details, not full study results.
Detailed Summary
Chronic spinal cord injury can permanently limit movement, independence, and daily function, making regenerative treatments relevant to preserving human capability. However, a treatment designed to repair damaged tissue must first undergo careful safety testing. This trial examined an experimental cell product, not an established therapy for restoring movement or extending lifespan.
The completed Phase 1 study enrolled 10 patients with chronic traumatic spinal cord injury at one center. Each participant was to receive one injection of Neuro-Cells into the fluid surrounding the spinal cord. The product contains fresh stem cells derived from the patient, with a separate batch prepared for each person. Neuroplast sponsored the study.
The study began on November 14, 2020, and was completed on March 10, 2023. Its stated purpose was to investigate safety. Crucially, the supplied abstract and registry details do not report adverse events, changes in movement or sensation, or other outcome data. Completion therefore confirms the study's status, not that Neuro-Cells proved safe, effective, or capable of repairing the spinal cord.
For patients and clinicians, this is an early research step rather than evidence supporting routine treatment. Using a patient's own cells does not eliminate risks from the product or injection procedure. Any future claim of restored function would require reported outcomes and stronger comparative evidence. The study does not establish benefits for healthy aging or support commercial stem cell treatments.
Interpretation is limited by the small sample, single study center, and open label design, meaning participants and researchers knew which treatment was given. The supplied description does not identify a comparison group or provide detailed safety monitoring methods, follow-up duration, or participant characteristics. This summary is based on the abstract only and supplied registry information, not full study results. Published safety findings and controlled trials are needed before drawing conclusions about clinical value.
Key Findings
- The completed Phase 1 trial enrolled 10 patients with chronic traumatic spinal cord injury.
- The intervention was a single Neuro-Cells injection into the fluid surrounding the spinal cord, using cells derived from each patient.
- The supplied abstract reports no safety outcomes or evidence of improved movement or sensation.
- Trial completion should not be interpreted as proof of safety, effectiveness, or readiness for routine clinical use.
Methodology
This was a single-center, open-label Phase 1 safety study of Neuro-Cells in 10 patients with chronic traumatic spinal cord injury. The protocol described one intrathecal administration of a fresh, patient-derived stem cell-containing product; the supplied description does not identify a comparison group.
Study Limitations
This summary is based on the abstract only and supplied registry details, not a full study report. The small, single-center, open-label design limits interpretation, and the supplied material reports neither adverse events nor functional outcomes. Detailed monitoring methods, follow-up duration, and participant characteristics are unavailable.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: